Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results